Paramedic Papers

Home Pain & sedation Intranasal equals subcutaneous ketamine for pain

Pain & sedation

Intranasal equals subcutaneous ketamine for pain

Intranasal Versus Subcutaneous Ketamine for the Treatment of Acute Traumatic Pain in the Emergency Department: A Randomized Clinical Trial
Annals of Emergency Medicine · Added 20 August 2026

RCT testing whether intranasal ketamine is non-inferior to subcutaneous for acute traumatic pain — both routes provided equivalent analgesia with minimal clinically important differences, though minor adverse events were more common with subcutaneous administration.

Study type
RCT
Design
Randomised double-blinded double-dummy trial
Participants
1,194 adults (599 subcutaneous, 595 intranasal) with acute musculoskeletal trauma
Main finding
Mean NRS reduction at 30 min −4.42 (intranasal) vs −3.70 (subcutaneous), difference −0.72 (95% CI −0.95 to −0.48), below the 1.3 clinically important threshold; more minor adverse events with subcutaneous
Caveat
ED-based study of adults aged 18–65 using fixed 20 mg dose; prehospital relevance unclear
Bottom line
Supports current practice

Why it matters in Australia (High relevance). Directly relevant to prehospital analgesia; IN route already used by many Australian services, confirms efficacy versus SC.

Learning goal

Weigh the benefits and harms of intranasal versus subcutaneous ketamine for managing acute traumatic pain in my practice.

Open in dashboard Read the paper (DOI) PubMed

More

Related papers on Pain & sedation